Analysed DERMATA THERAPEUTICS INC (DRMA:NASDAQ) News Sources
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
17-08-2026
yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
13-05-2026
yahoo.com
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
02-04-2026
yahoo.com
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
05-08-2026
yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
11-08-2026
yahoo.com
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
21-08-2026
yahoo.com
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
25-08-2026
yahoo.com
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
31-08-2026
yahoo.com
What is the current price of DERMATA THERAPEUTICS INC (DRMA:NASDAQ)?
The current price of DERMATA THERAPEUTICS INC (DRMA:NASDAQ) is $0.755.
DERMATA THERAPEUTICS INC (DRMA:NASDAQ) absolute price change since previous trading day?
The absolute price change of DERMATA THERAPEUTICS INC (DRMA:NASDAQ) since the previous trading day is $0.037.
DERMATA THERAPEUTICS INC (DRMA:NASDAQ) percentage price change since previous trading day?
The percentage price change of DERMATA THERAPEUTICS INC (DRMA:NASDAQ) since the previous trading day is 5.1532%.
What is the most recent average sentiment score for DERMATA THERAPEUTICS INC (DRMA:NASDAQ)?
The most recent average sentiment score for DERMATA THERAPEUTICS INC (DRMA:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for DERMATA THERAPEUTICS INC (DRMA:NASDAQ)?
The most recent sentiment for DERMATA THERAPEUTICS INC (DRMA:NASDAQ) is .
SEC-8K** Filing Available For DERMATA THERAPEUTICS INC (DRMA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.